40 results
8-K
EX-99.1
PASG
Passage Bio Inc
4 Mar 24
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
7:02am
securities to fund operations into Q4 2025.
Research and Development (R&D) Expenses: R&D expenses were $12.1 million for the quarter ended December 31
8-K
EX-99.2
PASG
Passage Bio Inc
4 Mar 24
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
7:02am
UPenn GTP Research Analytics and Vector Engineering Process/Analytic Development Passage CMC R&D Lab Proven Analytical Capabilities Integrated Process
8-K
EX-99.1
PASG
Passage Bio Inc
5 Jan 24
Regulation FD Disclosure
4:05pm
Analytics and Vector Engineering Process/Analytic Development Passage CMC R&D Lab Proven Analytical Capabilities Integrated Process Development GMP QC
8-K
EX-99.2
PASG
Passage Bio Inc
13 Nov 23
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
7:00am
. 99:662-666
6 Discovery UPenn GTP Research Analytics and Vector Engineering Process/Analytic Development Passage CMC R&D Lab Proven Analytical
8-K
EX-99.1
PASG
Passage Bio Inc
13 Nov 23
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
7:00am
and Development (R&D) Expenses: R&D expenses were $15.1 million for the quarter ended September 30, 2023, as compared to $15.4 million as of September
8-K
EX-99.1
q5ilrh8 g5hkjx0
7 Aug 23
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7:15am
8-K
EX-99.2
8yorw0epenqhnp rly
11 May 23
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
7:09am
8-K
EX-99.1
pc3c66 fa
11 May 23
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
7:09am
PRE 14A
ejz2xmadx9jn8nd5nkd
3 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.1
zfk3we n2kgooef8
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
EX-99.2
1pek rhe0p16lafb
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
EX-99.1
o912 fksspaifg5bso
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
8-K
EX-99.2
vial7j0wvbeizn
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
8-K
EX-99.1
o0spfn7li8ite
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
8-K
EX-99.2
krvzu66522s4utt2
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
8-K
EX-99.1
m3kpdvr38ro0cgwtk76
3 Mar 22
Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
7:15am
8-K
EX-99.2
lkixl
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.1
hiff 74prbh0ss2j
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am